Well if it's late breaking it won't come out of embargo on the...

First 11 Last

Share
Profile

Follow
harvett

4,947 Posts.

790

16/05/18

23:52

Post #: 33148588
Share

Originally posted by RBx ↑

Harvett, the procedure for abstract submission and review should be well known by anyone who follows biotech stocks, but it is clear that you have no idea.

As you can see from the following extracts from the ASCO website, abstracts had to be submitted by 13 February 2018. Edits are allowed, but not after 13 February. Late-breaking data can be submitted until 15 March, but only for randomised Phase II and III trials.

The abstract that will appear on the Noxopharm website on its day of presentation at ASCO will include data generated between 13 February and 1 June. The abstract that will be published by ASCO on 16 May is irrelevant.

What is the deadline for abstract submissions?
The deadline for abstract submissions is 11:59 PM (EST) on February 13, 2018.

Can I revise my abstract after it has been submitted?

Yes, you may edit your abstract on the submission website until the deadline of 11:59 PM (EST) on February 13, 2018. After the submission deadline, all requests for abstract changes must be submitted by the first author to the ASCO Abstracts team and will be reviewed on a case-by-case basis. Changes to data and results are not permitted.

Can I submit a late-breaking data submission? If so, what is the deadline?

Yes, there is an opportunity to submit a late-breaking data submission. However, a “shell” abstract must be submitted by February 13, 2018 (the “shell” includes all components of the abstract except the results and conclusions). ASCO will contact the first author for updated data to be submitted by March 15, 2018. Please refer to the late-breaking data policies on

Abstract Submission Guidelines

Late-Breaking Data Submissions

The ASCO late-breaking data policy allows for the submission of late-breaking data only for randomized phase II and III trials for which no preliminary data are available at the time of the abstract submission deadline (February 13, 2018)

Expand

Well if it's late breaking it won't come out of embargo on the 15th edt at all.

NOX Price at posting: 96.0¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

CHW

Cleo adds Royal Women's Hospital to its clinical trial for ovarian cancer diagnosis

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

There are more pages in this discussion • 21 more messages in this thread...

First 11 Last

Add NOX (ASX) to my watchlist

(20min delay)
Last 10.0¢		Change 0.000(0.00%)		Mkt cap ! $29.22M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
5	52445	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	14000	1

View Market Depth

No.	Vol.	Price($)
5	620344	0.110
1	9523	0.105
5	149890	0.100
1	25357	0.098
2	176978	0.096

Price($)	Vol.	No.
0.120	106914	1
0.125	128094	1
0.130	166171	3
0.135	199760	1
0.140	230213	8

Last trade - 10.11am 27/11/2024 (20 minute delay)

NOX (ASX) Chart

Day chart unavailable

Well if it's late breaking it won't come out of embargo on the...

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Cleo adds Royal Women's Hospital to its clinical trial for ovarian cancer diagnosis

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Buyers (Bids)

Sellers (Offers)